|
Daily Medical Update
Osteoporosis
Saturday, April 11, 2026
|
🔬 Practice‑Changing Findings
Evidence from RCTs and meta‑analyses published in the last 12 months.
|
Frontiers in endocrinology (2026) - Systematic Review
Key Findings
- Compared with placebo, alendronate, and teriparatide, anti-sclerostin antibodies significantly increased lumbar spine, total hip, and femoral neck BMD at 6 and 12 months.
- Versus denosumab, lumbar spine BMD increased more at 6 months (MD 3.68; 95% CI 0.34-7.01; p = 0.03) and 12 months (MD 5.20; 95% CI 3.19-7.21; p<0.00001), with no significant increase in cardiovascular risk.
📋 Practice Implication: For very high-risk postmenopausal patients, anti-sclerostin therapy is a strong anabolic option when rapid lumbar spine gains are the priority.
|
The lancet. Diabetes & endocrinology (2026) - Randomized Controlled Trial
Key Findings
- Total hip BMD increased 5.7% after 3 months of romosozumab followed by denosumab versus 6.0% with 12 months of romosozumab, meeting the prespecified non-inferiority threshold.
- Adverse events were balanced between groups, and the abbreviated regimen preserved BMD improvement versus 12 months of romosozumab while reducing injection burden.
📋 Practice Implication: A shortened romosozumab course followed by denosumab may expand access when cost, monthly visits, or tolerability make a full year impractical.
|
Clinical drug investigation (2026) - Meta-Analysis
Key Findings
- Across 13 randomized trials, denosumab increased BMD more than alendronate at the lumbar spine, femoral neck, distal radius, and total hip.
- In postmenopausal women, BMD improvement was greater at the lumbar spine at 6 months (p < 0.001) and at the femoral neck at 24 months (p < 0.001) versus non-postmenopausal participants.
📋 Practice Implication: When selecting between standard antiresorptives, denosumab has the clearest comparative advantage for multi-site BMD gains, especially in postmenopausal women.
|
Osteoporosis international (2025) - Randomized Controlled Trial
Key Findings
- Week-52 lumbar spine BMD increased 4.89% with RGB-14-P versus 4.55% with reference denosumab, meeting predefined equivalence criteria.
- CTX pharmacodynamic exposure was equivalent (geometric mean ratio 1.01; 95% CI 0.98-1.05), and fracture, immunogenicity, and safety outcomes were comparable between arms.
📋 Practice Implication: Approved denosumab biosimilars could lower treatment costs without sacrificing efficacy, safety, or pharmacodynamic effect.
|
Frontiers in endocrinology (2026) - Meta-Analysis
Key Findings
- High platelet-to-lymphocyte ratio was associated with higher vertebral fracture risk (OR 1.02; 95% CI 1.00-1.03; p = 0.01) in seven observational studies.
- Patients with vertebral fracture had higher PLR than those without fracture (SMD 1.78; 95% CI 0.32-3.25; p = 0.02), although sensitivity analyses showed instability.
📋 Practice Implication: PLR may help refine vertebral fracture risk assessment as an adjunct to established tools, but it should not replace standard fracture evaluation until cutoffs are standardized.
|
|
This osteoporosis update was dominated by therapy optimization studies: anti-sclerostin antibodies and abbreviated romosozumab-to-denosumab sequencing both increased bone mineral density, while denosumab outperformed alendronate and a phase 3 biosimilar matched reference denosumab. A separate meta-analysis linked higher platelet-to-lymphocyte ratio with vertebral fracture risk, suggesting a possible adjunctive risk-stratification marker, although heterogeneity limits immediate standalone use.
|
|